Vaccine Breakthrough Cripples Killer Gut Bacteria

Person holding their stomach with a graphic of intestines overlayed

Scientists have found a single weak spot shared by multiple deadly gut bacteria — and it could lead to one vaccine that stops them all.

Story Snapshot

Researchers identified a shared vulnerability in enzymes used by E. coli, Shigella, and related bacteria to break through the gut’s protective mucus layer.
Antibodies that target this one shared region can block all three enzymes and stop bacteria from causing infection.
A separate clinical trial of an oral Shigella vaccine showed 89% protection against infection in a controlled human study.
Despite promising lab results, no combination diarrheal vaccine is licensed yet, and experts don’t expect one widely available until the early 2030s.

The Gut Has a Wall — and Bacteria Know How to Tear It Down

Your intestines are lined with a thick layer of mucus. Think of it as a moat. Bacteria like enterotoxigenic Escherichia coli (E. coli) — the leading cause of traveler’s diarrhea — and Shigella can’t infect you unless they get through that moat first. To do it, they produce enzymes called mucinases. These enzymes chew through the mucus like a key unlocking a door. Without them, the bacteria can’t reach the gut wall and can’t make you sick.

Researchers at Washington University School of Medicine in St. Louis, working with teams at the University of Missouri and the International Centre for Diarrhoeal Disease Research in Bangladesh, studied three of these mucinase enzymes closely. They found something striking. All three share a common structural region — the same spot on each enzyme that makes it work. That shared spot is the vulnerability.

One Antibody to Neutralize Them All

Using blood samples from infected patients and volunteers who were deliberately exposed to the bacteria, the research team showed that antibodies targeting that one shared region could neutralize all three enzymes. Block the enzyme, block the bacteria. The lead enzyme they focused on is called EatA. When antibodies shut down EatA, they also knocked out the other two — SepA and Pic. The bacteria were stopped before they could breach the mucus barrier.

“This study establishes EatA as a viable vaccine candidate capable of providing protection across multiple pathogens,” said Zachary Berndsen, Ph.D., assistant professor of biochemistry at the University of Missouri and co-senior author of the study. The findings were published in the Proceedings of the National Academy of Sciences in 2026. The key word here is “candidate.” The lab results are compelling. Human clinical trials proving full protection still need to happen.

Meanwhile, a Separate Shigella Vaccine Just Hit 89% Protection

On a parallel track, a clinical trial of an oral vaccine called WRSs2 showed 89% protection against Shigella sonnei compared to a placebo in a controlled human infection model. Vaccinated participants also had less severe symptoms and shed fewer bacteria, which suggests the vaccine could slow transmission. Those results were published in The Lancet Infectious Diseases. That’s a serious number for a disease the World Health Organization lists as a priority pathogen.

Researchers discovered an “Achilles’ heel” shared by E. coli, Shigella, and other diarrhea-causing bacteria: enzymes they use to breach the gut’s protective mucus layer. By targeting this common vulnerability, scientists may be able to develop a single vachttps://t.co/LrynoD9K1C

— Michael W. Deem (@Michael_W_Deem) July 6, 2026

The WRSs2 trial did report temporary side effects in a small number of participants, requiring some dosing adjustments. No serious adverse events occurred, but it signals the vaccine still needs refinement before it’s ready for broad use. It also targets only Shigella sonnei — one strain. The EatA-based approach, by contrast, aims to cover both E. coli and multiple Shigella strains with a single shot. That’s the bigger prize, and it’s still years away from human trials.

Why This Pipeline Has Stalled Before — and Could Again

There is no licensed vaccine today against Shigella or enterotoxigenic E. coli, despite decades of research. Nine Shigella vaccine candidates are currently in clinical trials, and the World Health Organization does not expect a widely available vaccine until the early 2030s. That gap between a promising lab result and a licensed product has a name in the field: the “valley of death.” Regulatory requirements for multi-pathogen vaccines are complex. Manufacturing at scale adds more hurdles. Prior broad-spectrum candidates, like the YncE beta-propeller protein, showed strong early promise and then stalled.

What Makes This Discovery Different — and What Still Has to Happen

The EatA finding is genuinely significant because it gives vaccine designers a precise molecular target. That’s called rational vaccine design, and it’s a more efficient path than earlier trial-and-error approaches. But the current study demonstrates in vitro results — meaning test tubes and lab models, not human bodies. Cross-protection against E. coli in a controlled human trial has not yet been demonstrated. The science is sound. The road from sound science to a licensed vaccine, however, runs through years of clinical trials, regulatory review, and manufacturing scale-up.

For travelers, parents of young children, and the hundreds of millions of people in developing countries hit hardest by diarrheal disease, this research is real progress. It’s not a vaccine yet. But for the first time, scientists may have found the one lock that opens every door — and that matters.